IONS IONIS PHARMACEUTICALS INC Company Mergers 8-K Filing 2023 - License Agreement with Otsuka Pharmaceutical Ionis Pharmaceuticals, Inc. has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. for exclusive rights in Europe to commercialize donidalorsen, a treatment for hereditary angioedema (HAE).Get access to all SEC 8-K filings of the IONIS PHARMACEUTICALS INC